A novel mutation in SIRT1-AS leading to a decreased risk of HCC

Liu,Junbin; Wu,Weihong; Jin,Junhua

doi:10.3892/or.2015.4205

A novel mutation in SIRT1-AS leading to a decreased risk of HCC

Authors:
- Junbin Liu
- Weihong Wu
- Junhua Jin
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, The Affiliated Hospital of Inner Mongolia Medical College, Hohhot, Inner Mongolia, P.R. China, Outpatient Office of The Affiliated Hospital of Inner Mongolia Medical College, Hohhot, Inner Mongolia, P.R. China
Published online on: August 19, 2015 https://doi.org/10.3892/or.2015.4205
Pages: 2343-2350

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Natural antisense transcripts (NATs) have recently been associated with the development of human cancers. However, the interrelationship between NATs and their sense transcripts in hepatocellular carcinoma (HCC) has not been well-characterized. The aim of the present study was to characterize the AS lncRNA SIRT1-AS, which suppressed the miRNA-induced translational repression of SIRT1 mRNA by masking the miR-29c binding site on the SIRT1 3'UTR. A 763-nucleotide (nt), single-exon NAT transcribed from the antisense strand of SIRT1 gene, designated as SIRT1-AS, was identified using strand-specific RT-PCR and northern blot analyses. SIRT1-AS overexpression promoted the proliferation of the human HCC cell lines by upregulating the SIRT1 protein level. The mechanism was that SIRT1-AS bound to SIRT1 mRNA at 3'UTR, masked the miR-29c binding site and stabilized SIRT1 mRNA. A single-nucleotide mutation (622U>C) in the SIRT1-AS sequence was found when we used gene sequencing as an assistant approach for HCC diagnosis. Bioinformatics and the RNase protection assay revealed that the mutation led to a marked alteration in the secondary structure of SIRT1-AS and caused its inability to bind with SIRT1 mRNA. Overexpression of this mutant did not have a promoting effect on HCC cell proliferation. Moreover, the mean level of SIRT1-AS was much higher in the HCC patients compared to non-hepatopathy volunteers (P<0.01), whereas the opposite effect was observed for the mutant ratio. The odds ratio (OR) analysis also suggested the 622C mutation reduced the risk of HCC. Taken together, we identified a novel mutation in SIRT1-AS leading to a decreased risk of HCC. The results of the present study suggest that the 622C mutant of SIRT1 antisense transcript suppresses HCC cell line proliferation, decreases the risk of HCC and is a potential target for gene therapy.

View Figures

View References

1	Werner A and Berdal A: Natural antisense transcripts: Sound or silence? Physiol Genomics. 23:125–131. 2005. View Article : Google Scholar : PubMed/NCBI
2	He Y, Vogelstein B, Velculescu VE, Papadopoulos N and Kinzler KW: The antisense transcriptomes of human cells. Science. 322:1855–1857. 2008. View Article : Google Scholar : PubMed/NCBI
3	Katayama S, Tomaru Y, Kasukawa T, Waki K, Nakanishi M, Nakamura M, Nishida H, Yap CC, Suzuki M, Kawai J, et al FANTOM Consortium: Antisense transcription in the mammalian transcriptome. Science. 309:1564–1566. 2005. View Article : Google Scholar : PubMed/NCBI
4	Faghihi MA and Wahlestedt C: Regulatory roles of natural antisense transcripts. Nat Rev Mol Cell Biol. 10:637–643. 2009. View Article : Google Scholar : PubMed/NCBI
5	Pelechano V and Steinmetz LM: Gene regulation by antisense transcription. Nat Rev Genet. 14:880–893. 2013. View Article : Google Scholar : PubMed/NCBI
6	Magistri M, Faghihi MA, St Laurent G III and Wahlestedt C: Regulation of chromatin structure by long noncoding RNAs: Focus on natural antisense transcripts. Trends Genet. 28:389–396. 2012. View Article : Google Scholar : PubMed/NCBI
7	Bertozzi D, Iurlaro R, Sordet O, Marinello J, Zaffaroni N and Capranico G: Characterization of novel antisense HIF-1α transcripts in human cancers. Cell Cycle. 10:3189–3197. 2011. View Article : Google Scholar : PubMed/NCBI
8	Bhan A, Hussain I, Ansari KI, Kasiri S, Bashyal A and Mandal SS: Antisense transcript long noncoding RNA (lncRNA) HOTAIR is transcriptionally induced by estradiol. J Mol Biol. 425:3707–3722. 2013. View Article : Google Scholar : PubMed/NCBI
9	Su WY, Li JT, Cui Y, Hong J, Du W, Wang YC, Lin YW, Xiong H, Wang JL, Kong X, et al: Bidirectional regulation be tween WDR83 and its natural antisense transcript DHPS in gastric cancer. Cell Res. 22:1374–1389. 2012. View Article : Google Scholar : PubMed/NCBI
10	Haigis MC and Guarente LP: Mammalian sirtuins - emerging roles in physiology, aging, and calorie restriction. Genes Dev. 20:2913–2921. 2006. View Article : Google Scholar : PubMed/NCBI
11	Michan S and Sinclair D: Sirtuins in mammals: Insights into their biological function. Biochem J. 404:1–13. 2007. View Article : Google Scholar : PubMed/NCBI
12	Finkel T, Deng CX and Mostoslavsky R: Recent progress in the biology and physiology of sirtuins. Nature. 460:587–591. 2009. View Article : Google Scholar : PubMed/NCBI
13	Chang HC and Guarente L: SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab. 25:138–145. 2014. View Article : Google Scholar : PubMed/NCBI
14	Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, et al: Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell. 127:1109–1122. 2006. View Article : Google Scholar : PubMed/NCBI
15	Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA and Mayo MW: Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 23:2369–2380. 2004. View Article : Google Scholar : PubMed/NCBI
16	Bai L, Pang WJ, Yang YJ and Yang GS: Modulation of Sirt1 by resveratrol and nicotinamide alters proliferation and differentiation of pig preadipocytes. Mol Cell Biochem. 307:129–140. 2008. View Article : Google Scholar
17	Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu Y, Patel P, Bronson R, Appella E, Alt FW and Chua KF: Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA. 100:10794–10799. 2003. View Article : Google Scholar : PubMed/NCBI
18	Lee JT and Gu W: SIRT1: Regulator of p53 deacetylation. Genes Cancer. 4:112–117. 2013. View Article : Google Scholar : PubMed/NCBI
19	Bae HJ, Noh JH, Kim JK, Eun JW, Jung KH, Kim MG, Chang YG, Shen Q, Kim SJ, Park WS, et al: MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene. 33:2557–2567. 2014. View Article : Google Scholar
20	He Y, Meng XM, Huang C, Wu BM, Zhang L, Lv XW and Li J: Long noncoding RNAs: Novel insights into hepatocellular carcinoma. Cancer Lett. 344:20–27. 2014. View Article : Google Scholar
21	Faghihi MA, Modarresi F, Khalil AM, Wood DE, Sahagan BG, Morgan TE, Finch CE, St Laurent G III, Kenny PJ and Wahlestedt C: Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of β-secretase. Nat Med. 14:723–730. 2008. View Article : Google Scholar : PubMed/NCBI
22	Li K, Blum Y, Verma A, Liu Z, Pramanik K, Leigh NR, Chun CZ, Samant GV, Zhao B, Garnaas MK, et al: A noncoding antisense RNA in tie-1 locus regulates tie-1 function in vivo. Blood. 115:133–139. 2010. View Article : Google Scholar :